Compare Cassava Sciences Inc (FLNA) vs Ermenegildo Zegna N.V. Ordinary Shares (ZGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Ermenegildo Zegna N.V. Ordinary Shares — how do they compare? Cassava Sciences Inc trades at $0.71 (market cap $35.91M), while Ermenegildo Zegna N.V. Ordinary Shares trades at $12.8 (market cap $3.48B). The key difference: Ermenegildo Zegna N.V. Ordinary Shares is far larger — about 96.9× Cassava Sciences Inc's market cap, and Ermenegildo Zegna N.V. Ordinary Shares pays a 1.06% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 38 Days and Ermenegildo Zegna N.V. Ordinary Shares for 0 Days on average.
| FLNA | ZGN | |
|---|---|---|
Market Cap | $35.91M | $3.48B |
Volume | 323,246 | 1,076,161 |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $15.25 |
52-Week Low | $0.68 | $8.69 |
Typical Hold Time | 38 Days | 0 Days |
Enterprise Value | -$46.77M | $4.43B |
Dividend Yield | — | 1.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.7316, down 4.93% today, amid bearish technical signals despite recent FDA progress. The stock shows negative profitability with ROE at -55.79% and consistent negative cash flow, though it has beaten EPS estimates for three consecutive quarters. Analyst consensus remains positive with 8 buy ratings versus 4 holds.
The outlook hinges on clinical development success, particularly the Phase 2a study for TSC-related epilepsy. Investment opportunity exists if trials progress favorably, but risks include cash burn, regulatory hurdles, and persistent losses. Current valuation metrics like EV/EBITDA of 1.11 suggest potential upside if execution improves.
ZGN trades at $12.94, up 2.7% with a neutral technical outlook. The stock shows mixed fundamentals with a high P/E of 38.5 but strong gross margins of 67.58%. Recent earnings beat expectations in three of the last four quarters, though Q2 2026 missed estimates. Analyst consensus is bullish with a $14.12 price target and 66.7% buy ratings. Revenue growth continues with 2025 reaching $1.92B, though net margins compressed to 3.98%.
ZGN presents a growth opportunity with expanding DTC momentum and margin potential, but faces valuation concerns and competitive pressures. The stock's upside depends on sustained earnings growth and successful execution of the retail-first strategy amidst fashion sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Ermenegildo Zegna N.V. Ordinary Shares
Ermenegildo Zegna N.V. is a luxury fashion group whose brands include Zegna, Thom Browne, and Tom Ford Fashion. The company operates a vertically integrated supply chain, sourcing wool from its own Australian farm through to finished garment production.
Read more on ZGN →
